[{"orgOrder":0,"company":"Lannett Company, Inc.","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Lannett Company, Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lannett Company, Inc. \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Lannett Company, Inc. \/ Cediprof"},{"orgOrder":0,"company":"Mannkind","sponsor":"Vertice Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mannkind \/ Vertice Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mannkind \/ Vertice Pharma"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IBSA Institut Biochimique \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IBSA Institut Biochimique \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Mark Cuban Cost Plus Drug Company","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company","highestDevelopmentStatusID":"12","companyTruncated":"IBSA Institut Biochimique \/ Mark Cuban Cost Plus Drug Company"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Levothyroxine Sodium","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Xeris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Xeris Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Xeris Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Levothyroxine Sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : XP-8121 (levothyroxine) is a Investigational hormome, administered via Subcutaneous injection for the treatment of acquired thyroid disease.

Product Name : XP-8121

Product Type : Small molecule

Upfront Cash : Not Applicable

May 30, 2024

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : XP-8121 (levothyroxine) is a Investigational Subcutaneous injection thus indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary hypothyroidism),

Product Name : XP-8121

Product Type : Small molecule

Upfront Cash : Not Applicable

June 21, 2023

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Levothyroxine sodium is a medicine used to treat an underactive thyroid gland (hypothyroidism). The thyroid gland makes thyroid hormones which help to control energy levels and growth. Levothyroxine is taken to replace the missing thyroid hormone thyroxi...

Product Name : Levothyroxine Sodium-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

March 28, 2023

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Rare Diseases and Disorders

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Tirosint capsules is the leading branded gel capsule formulation of levothyroxine sodium in the US. It is formulated without excipients that can cause tolerability and drug absorption problems commonly observed with traditional levothyroxine tablet thera...

Product Name : Tirosint

Product Type : Small molecule

Upfront Cash : Undisclosed

March 07, 2023

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Mark Cuban Cost Plus Drug Company

Deal Size : Undisclosed

Deal Type : Agreement

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : XP-8121 (levothyroxine sodium) is administered when the body is deficient in the endogenous hormone and indicated for acquired thyroid disease (primary hypothyroidism), in cases of decreased secretion of TSH from the anterior pituitary gland (secondary h...

Product Name : XP-8121

Product Type : Small molecule

Upfront Cash : Not Applicable

December 15, 2022

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : XP-8121 is a novel formulation that could potentially mitigate challenges linked to oral formulations, such as identification of an ideal dose due to absorption variation and medication adherence for patients who have difficulty maintaining a stable, the...

Product Name : XP-8121

Product Type : Small molecule

Upfront Cash : Not Applicable

September 01, 2021

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The study examined the potency and consistency of Tirosint-SOL marketed by IBSA Pharma Inc, using the same methodology as the previous study to determine the degree to which the product maintains its labeled potency over a five-week period.

Product Name : Tirosint-SOL

Product Type : Small molecule

Upfront Cash : Not Applicable

April 30, 2021

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Vertice will make a specified quarterly payment to MannKind to defray the costs of the additional promotional activity and will pay MannKind royalties on gross profit resulting from all sales of Thyquidity.

Product Name : Thyquidity

Product Type : Small molecule

Upfront Cash : Undisclosed

December 17, 2020

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Vertice Pharma

Deal Size : Undisclosed

Deal Type : Agreement

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The companies have entered into an interim exclusive supply and distribution agreement for Cediprof's FDA approved Levothyroxine Sodium Tablets USP. Lannett to Commence Marketing on August 3, 2020.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

July 16, 2020

Lead Product(s) : Levothyroxine Sodium

Therapeutic Area : Endocrinology

Highest Development Status : Approved

Sponsor : Cediprof

Deal Size : Undisclosed

Deal Type : Agreement

blank